Daniel Wilkey

Mr. Daniel Wilkey

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
RBRumeysa Biyik-Sit
Rumeysa Biyik-Sit
TKTraci Kruer
Traci Kruer
SDSusan Dougherty
Susan Dougherty
JBJames A. Bradley
James A. Bradley
DWDaniel Wilkey
Daniel Wilkey
BCBrian Clem
Brian Clem
An elevated expression of phosphoserine aminotransferase 1 (PSAT1) has been observed in multiple tumor types and is associated with poorer clinical outcomes. Although PSAT1 is postulated to promote tumor growth through its enzymatic function within the serine synthesis pathway (SSP), its role in cancer progression has not been fully characterized. Here, we explore a putative non-canonical function of PSAT1 that contributes to lung tumor progression. Biochemical studies found that PSAT1 selectively interacts with pyruvate kinase M2 (PKM2). Amino acid mutations within a PKM2-unique region significantly reduced this interaction. While PSAT1 loss had no effect on cellular pyruvate kinase activity and PKM2 expression in non-small-cell lung cancer (NSCLC) cells, fractionation studies demonstrated that the silencing of PSAT1 in epidermal growth factor receptor (EGFR)-mutant PC9 or EGF-stimulated A549 cells decreased PKM2 nuclear translocation. Further, PSAT1 suppression abrogated cell migration in these two cell types whereas PSAT1 restoration or overexpression induced cell migration along with an elevated nuclear PKM2 expression. Lastly, the nuclear re-expression of the acetyl-mimetic mutant of PKM2 (K433Q), but not the wild-type, partially restored cell migration in PSAT1-silenced cells. Therefore, we conclude that, in response to EGFR activation, PSAT1 contributes to lung cancer cell migration, in part, by promoting nuclear PKM2 translocation.

23 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
GSGabriela Schneider
Gabriela Schneider
AKAlagammai Kaliappan
Alagammai Kaliappan
TNTaylor Q. Nguyen
Taylor Q. Nguyen
Robert BuscagliaRobert Buscaglia
Robert Buscaglia
GBGuy Brock
Guy Brock
NGNichola C. Garbett
Nichola C. Garbett
Early detection of lung cancer (LC) significantly increases the likelihood of successful treatment and improves LC survival rates. Currently, screening (mainly low-dose CT scans) is recommended for individuals at high risk. However, the recent increase in the number of LC cases unrelated to the well-known risk factors, and the high false-positive rate of low-dose CT, indicate a need to develop new, non-invasive methods for LC detection. Therefore, we evaluated the use of differential scanning calorimetry (DSC) for LC patients’ diagnosis and predicted survival. Additionally, by applying mass spectrometry, we investigated whether changes in O- and N-glycosylation of plasma proteins could be an underlying mechanism responsible for observed differences in DSC curves of LC and control subjects. Our results indicate selected DSC curve features could be useful for differentiation of LC patients from controls with some capable of distinction between subtypes and stages of LC. DSC curve features also correlate with LC patients’ overall/progression free survival. Moreover, the development of classification models combining patients’ DSC curves with selected plasma protein glycosylation levels that changed in the presence of LC could improve the sensitivity and specificity of the detection of LC. With further optimization and development of the classification method, DSC could provide an accurate, non-invasive, radiation-free strategy for LC screening and diagnosis.

1 January 2019 in Cellular Signalling
Verified
Journal Article
Closed access
JHJosiah Hardesty
Josiah Hardesty
BWBanrida Wahlang
Banrida Wahlang
KFK. Cameron Falkner
K. Cameron Falkner
HSHongxue Shi
Hongxue Shi
JJJian Jin
Jian Jin
MCMatthew Cave
Matthew Cave

27 February 2021 in Viruses
Verified
Journal Article
Open access
PDF file
TLTrey Landers
Trey Landers
DWDaniel Wilkey
Daniel Wilkey
MMMichael Merchant
Michael Merchant
TMThomas C. Mitchell
Thomas C. Mitchell
Kevin SokoloskiKevin Sokoloski
Kevin Sokoloski
Alphaviruses are arthropod-borne RNA viruses which can cause either mild to severe febrile arthritis which may persist for months, or encephalitis which can lead to death or lifelong cognitive impairments. The non-assembly molecular role(s), functions, and protein–protein interactions of the alphavirus capsid proteins have been largely overlooked. Here we detail the use of a BioID2 biotin ligase system to identify the protein–protein interactions of the Sindbis virus capsid protein. These efforts led to the discovery of a series of novel host–pathogen interactions, including the identification of an interaction between the alphaviral capsid protein and the host IRAK1 protein. Importantly, this capsid–IRAK1 interaction is conserved across multiple alphavirus species, including arthritogenic alphaviruses SINV, Ross River virus, and Chikungunya virus; and encephalitic alphaviruses Eastern Equine Encephalitis virus, and Venezuelan Equine Encephalitis virus. The impact of the capsid–IRAK1 interaction was evaluated using a robust set of cellular model systems, leading to the realization that the alphaviral capsid protein specifically inhibits IRAK1-dependent signaling. This inhibition represents a means by which alphaviruses may evade innate immune detection and activation prior to viral gene expression. Altogether, these data identify novel capsid protein–protein interactions, establish the capsid–IRAK1 interaction as a common alphavirus host–pathogen interface, and delineate the molecular consequences of the capsid–IRAK1 interaction on IRAK1-dependent signaling.

6 May 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
ARAnand R. Ramalingam
Anand R. Ramalingam
CKCory Kucera
Cory Kucera
SSShweta Srivastava
Shweta Srivastava
RPRomith Paily
Romith Paily
DSDawson Stephens
Dawson Stephens
ACAlex Carll
Alex Carll
Background: Although e‐cigarettes provide an alternative to conventional smoking, the cardiovascular impacts of e‐cigarette use are unresolved. The popularity of menthol e‐cigarettes has surged recently and may escalate further with bans on combustible menthol cigarettes and e‐cigarette flavors other than menthol and tobacco. Despite recent evidence in mice that menthol e‐cigarettes acutely induce cardiac arrhythmias, the impacts of repeated menthol e‐cigarette use on cardiovascular function and the cardiac proteome remain unclear. We therefore investigated the acute and persistent cardiovascular effects of menthol e‐cigarettes in a mouse model. Methods and Results: Adult C57BL/6J mice with ECG and blood pressure radiotransmitters were exposed to e‐cigarette aerosols (180–270 puffs/day; n=4–8/group). One‐day exposures to nicotine‐containing e‐cigarette aerosols depressed heart rate variability regardless of flavor, but menthol e‐cigarette aerosols uniquely increased heart rate and urine epinephrine and elicited spontaneous ventricular premature beats. Menthol e‐cigarette aerosols consistently increased blood pressure acutely, and this effect recurred throughout the 20‐day regimen. Pretreatment with atenolol abolished e‐cigarette–induced arrhythmias, suggesting the involvement of β1‐adrenoceptors. After 4 weeks of exposure to JUUL Menthol aerosol, mice had basal sinus bradycardia that persisted up to 3 weeks after exposure cessation. After cessation, e‐cigarette–exposed mice also exhibited an altered chronotropic response to restraint stress and prolonged ventricular repolarization (corrected QT interval). Integrated proteomic and phosphoproteomic analysis of cardiac tissue harvested from mice exposed to menthol e‐cigarette aerosols for 5 and 20 days revealed molecular signatures of dilated and arrhythmogenic cardiomyopathy. Conclusions: Exposure to menthol e‐cigarette aerosols induces persistent cardiovascular autonomic imbalance in vivo. These findings raise the possibility of similar effects in humans using mentholated e‐cigarettes.

16 February 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DCDawn Caster
Dawn Caster
EKErik A. Korte
Erik A. Korte
MMMichael Merchant
Michael Merchant
JKJon B. Klein
Jon B. Klein
MBMichelle Barati
Michelle Barati
David W. Wayne PowellDavid W. Wayne Powell
David W. Wayne Powell
Kidney involvement in systemic lupus erythematosus (SLE)—termed lupus nephritis (LN)—is a severe manifestation of SLE that can lead to end-stage kidney disease (ESKD). LN is characterized by immune complex deposition and inflammation in the glomerulus. We tested the hypothesis that autoantibodies targeting podocyte and glomerular cell proteins contribute to the development of immune complex formation in LN. We used Western blotting with SLE sera from patients with and without LN to identify target antigens in human glomerular and cultured human-derived podocyte membrane proteins. Using liquid chromatography-tandem mass spectrometry (LC-MS/MS), we identified the proteins in the gel regions corresponding to reactive bands observed with sera from LN patients. We identified 102 proteins that were present in both the podocyte and glomerular samples. We identified 10 high-probability candidates, including moesin, using bioinformatic analysis. Confirmation of moesin as a target antigen was conducted using immunohistochemical analysis (IHC) of kidney biopsy tissue and enzyme-linked immunosorbent assay (ELISA) to detect circulating antibodies. By IHC, biopsies from patients with proliferative lupus nephritis (PLN, class III/IV) demonstrated significantly increased glomerular expression of moesin (p < 0.01). By ELISA, patients with proliferative LN demonstrated significantly increased antibodies against moesin (p < 0.01). This suggests that moesin is a target glomerular antigen in lupus nephritis.